OBJECTIVES To conduct a pharmacoeconomic analysis of oral drugs, tegafur vs capecitabine, for advanced colorectal cancer (CRC) in adult patients. METHODS Indirect comparison and network meta-analysis of clinical efficacy and safety of tegafur vs capecitabine and tegafur + calcium folinate vs capecitabine were performed. Cost-minimization analysis (CMA) with calculation of cost minimization difference was used for economic evaluation of studied drugs.   RESULTS There was no statistically significant difference in the full and partial objective tumor response between oral tegafur (both in monotherapy or in combination with calcium folinate) and capecitabine for advanced CRC treatment in an indirect comparison and network meta-analysis. Capecitabine vs tegafur + calcium folinate has less  3-4^th grade stomatitis but there was no difference in the incidence of diarrhea and 3-4^th grade nausea/vomiting. There was no difference in safety between tegafur and capecitabine monotherapy in terms of incidence of diarrhea, vomiting, stomatitis/mucositis. The hand-foot syndrome occurrred in less than 5% in case of tegafur. Tegafur (in monotherapy or in combination with calcium folinate) is less costly than capecitabine. The difference in costs in favor of tegafur monotherapy amounted to €1,956.97 per 1 patient per 6 months or €3,778.53 per year;of tegafur + calcium folinate - €2,168.12 and €4,220.06 per 1 patient per 6 and 12 months, respectively. CONCLUSIONS Tegafur is a cost-saving option compared with capecitabine with similar efficacy and safety.